Levomilnacipran (Fetzima) for major depressive disorder

American Family Physician

Volumn 92, Issue 8, 2015, Pages 727-731

  Zaman, Samira ^a   McLaughlin, Maura R ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; KETOCONAZOLE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; TRAMADOL; TRIPTAN DERIVATIVE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE;

ARTICLE; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; ADULT; CARDIOVASCULAR SYSTEM; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DRUG EFFECTS; PATHOPHYSIOLOGY; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEROTONIN SYNDROME; SUICIDE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR SYSTEM; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TECHNIQUES; SEROTONIN SYNDROME; SUICIDAL IDEATION; SUICIDE; TREATMENT OUTCOME;

EID: 84944463557     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Fetzima (levomilnacipran hydrochloride capsule, extended release). DailyMed. Bethesda, Md.: U.S. National Library of Medicine. Updated July 2014. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f371258d-91b3-4b6a-ac99-434a1964c3af. Accessed January 21, 2015.
2. Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study [published correction appears in Clin Drug Investig. 2013;33(11):861]. Clin Drug Investig. 2013;33(10):761-771.
3. Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67(11):1089-1104.
4. Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixeddose, placebo-controlled study. J Psychiatry Neurosci. 2014;39(1):40-49.
5. Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(1):47-56.
6. Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-ofconcept study. J Clin Psychiatry. 2013;74(4):363-369.
7. Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebocontrolled study. J Clin Psychiatry. 2013;74(3):242-248.
8. Shiovitz T, Greenberg WM, Chen C, Forero G, Gommoll CP. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder. Innov Clin Neurosci. 2014;11(1-2):10-22.